Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2

Drug Metabolism and Disposition

Volumn 25, Issue 11, 1997, Pages 1298-1303

  Shet, Manjunath S ^a   McPhaul, Michael ^a   Fisher, Charles W ^a   Stallings, Nancy R ^a   Estabrook, Ronald W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANDROGEN RECEPTOR; CAFFEINE; CYTOCHROME P450; ESTRADIOL; FLUTAMIDE; IMIPRAMINE; KETOCONAZOLE; PHENACETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG METABOLISM; DRUG POTENCY; ENZYME PURIFICATION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

ANDROGEN ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTRANSFORMATION; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; FLUTAMIDE; HUMANS; MICROSOMES, LIVER; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 0030725274     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. D. G. McLeod: Antiandrogenic drugs. Cancer 71, 1046-1049 (1993).
2. D. G. McLeod, R. C. Benson, Jr., M. A. Eisenberger, E. D. Crawford, B. A. Blumenstein, D. Spicer, and J. T. Spaulding: The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer 72, 3870-3873 (1993).
3. M. Schulz, A. Schmoldt, F. Donn, and H. Becker: The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur. J. Clin. Pharmacol. 34, 633-636 (1988).
4. B. Katchen and S. Buxbaum: Disposition of a new, nonsteroid, antiandrogen, alpha,alpha,alpha-trifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J. Clin. Endocrinol. Metab. 41, 373-379 (1975).
5. J. L. Gomez, A. Dupont, L. Cusan, M. Tremblay, R. Suburu, M. Lemay, and F. Labne: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am. J. Med. 92, 465-470 (1992).
6. A. Berson, C. Wolf, C. Chachaty, C. Fisch, D. Fau, D. Eugene, J. Loeper, J. C. Gauthier, P. Beaune, D. Pompon et al.: Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J. Pharmacol. Exp. Ther. 265, 366-372 (1993).
7. D. Fau, D. Eugene, A. Berson, P. Letteron, B. Fromenty, C. Fisch, and D. Pessayre: Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J. Pharmacol. Exp. Ther. 269, 954-962 (1994).
8. D. J. Newton, R. W. Wang, and A. Y. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
9. M. S. Shet, C. W. Fisher, P. L. Holmans, and R. W. Estabrook: Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc. Natl. Acad. Sci. U.S.A. 90, 11748-11752 (1993).
10. M. S. Shet, C. W. Fisher, M. P. Arlotto, C. H. L. Shackleton, P. L. Holmans, C. A. Martin-Wixtrom, Y. Saeki, and R. W. Estabrook: Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of Bovine P450 17A and Rat NADPH-P450 reductase. Arch. Biochem. Biophys. 311, 402-417 (1994).
11. P. L. Holmans, M. S. Shet, C. A. Martin-Wixtrom, C. W. Fisher, and R. W. Estabrook: The high level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5. Arch. Biochem. Biophvs. 312, 554-565 (1994).
12. A. L. Shen, T. D. Porter, T. E. Wilson, and C. B. Kasper: Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 264, 7584-7589 (1989).
13. M. S. Shet, K. M. Faulkner, P. L. Holmans, C. W. Fisher, and R. W. Estabrook: The Effect of cytochrome b5, NADPH-P450 reductase, and lipid on the 6β-hydroxylation of Testosterone catalyzed by a human P450 3A4 fusion protein. Arch. Biochem. Biophys. 318, 314-321 (1995).
14. C. W. Fisher, D. L. Caudle, C. Martin-Wixtrom, L. C. Quattrochi, R. H. Tukey, M. R. Waterman, and R. W. Estabrook: High level expression of functional human cytochrome P450 1A2 in Eschericia coli. FASEB J.6, 759-764 (1992).
15. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes: II. solubilization, purification, and properties. J. Biol. Chem. 239, 2379-2385 (1964).
16. M. M. Bradford: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
17. P. J. Southern and P. Berg: Transformation of mammalian cells to antibiotic resistance with a bacterial gene under the control of the SV40 early region promoter. J. Mol. Appl. Genet. 1, 327-341 (1982).
18. S. Andersson, D. L. Davis, H. Dahlback, H. Jornvall, and D. W. Russell. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme J. Biol. Chem. 264, 8222-8229 (1989).
19. F. L. Graham and A. J. Van der Eb: A new technique for the assay of infectivity of human adenovirus 5 DNA Virology 52, 456-467 (1973).
20. T. S. Gao, M. Marcelli, and M. J. McPhaul. Transcription transactivation and transient expression of the human androgen receptor. J. Steroid Biochem. Mol. Biol. 59, 9-20 (1996).
21. D. W. Nebert, A. Puga, and V. Vasiliou: Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann. N. Y. Acad. Sci. 685, 624-640 (1993).
22. A. Poland and E. Glover: Studies on the mechanism of induction of aryl hydrocarbon hydroxylase activity: evidence for an induction receptor. In "In Vitro Metabolic Activation in Mutagenesis Testing (F. J. de Serres et al., eds.), pp. 277-291. Amsterdam, North-Holland Publishing, 1976.
23. B. Zumoff, J. Fishman, S. Freed, J. Levin, W. F. Whitmore, L. Hellman, and D. K. Fukushima: Effect of flutamide on estradiol metabolism. J. Clin. Endocrinol. Metab. 49, 467-468 (1979).